On Jul. 7, 2022, Novavax announced that the European Commission had approved a variation to allow SK bioscience to manufacture and supply the active substance in the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine to the European Union (EU). This variation approval enabled Novavax to manufacture product for the EU from two major vaccine suppliers – SK bioscience and the Serum Institute of India.

SK bioscience manufactured drug substance and drug product of Nuvaxovid for the South Korean market and manufactured drug substance for the EU as well.

The Novavax COVID-19 vaccine (NVX-CoV2373) has not yet been authorized for use in the U.S. and the trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.